– Family business impresses again in all four competition areas
– Site development and digitalization as strategic investment priorities
– New skilled workforce potentials and lifelong learning in focus

Vetter, a partner of global pharmaceutical and biotech companies for the manufacturing of life-enha…

– Pharmaceutical service provider celebrates groundbreaking with project partners and representatives from land and region
– Production building with 50,000 m² area marks the start of construction work
– New location is part of global growth and investment initiatives

Vetter, one of the world's leading…

Construction measures at the new clinical site in Des Plaines are proceeding on schedule
Expansion of infrastructure at the Austrian site strengthens clinical processes
Established site in Skokie continues to show positive results

Vetter, one of the world's leading pharmaceutical service providers in t…

– Important Industry Recognition for CDMOs
– Selection based on quantitative metrics and verified reviews from the biopharma industry
– The award emphasizes the trust of the industry and customers in Vetter

Vetter, a globally operating service provider for pharmaceutical and biotech companies specializ…

– Initial investment volume in Saarlouis of 480 million euros
– Construction start in the second quarter of 2026
– Production of medications planned to start in 2031

Vetter, one of the world's leading pharmaceutical service providers for the manufacturing of injectable medicines, confirms during a meet…

– New studies demonstrate high user-friendliness and performance
– Design finalized and preparations for serial production initiated
– New features set a new standard

Vetter, a partner of global pharmaceutical and biotech companies for the manufacturing of life-improving medications, is working intensi…

– Over 35 years at Vetter, including 23 years in management
– Remains with the company in an advisory role
– Transition to an experienced leadership team strategically planned early

After more than 35 years at Vetter, including 23 years as Managing Director, Thomas Otto is stepping down from his manage…

– Completion is scheduled for the end of 2029
– Modern location with a holistic approach for state-of-the-art manufacturing processes
– Conditions created for increased capacities in early clinical filling

Vetter, a global partner of pharmaceutical and biotech companies for the production of some life…

– Strategic focus and long-term oriented actions convince once again
– Combining economic success and sustainability
– Family business in the spotlight for the 2025 award

Vetter, a partner to global pharmaceutical companies for the production of some life-saving medications, was once again awarded as a…

– Investments in sustainable energy infrastructures
– Further reduction of CO2 emissions
– Expansion of commitment to training and integration

The pharmaceutical service provider Vetter has published its fourth sustainability report. It demonstrates: the globally active family business pursues its am…